Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population
Metadatos
Afficher la notice complèteAuteur
López Cortes, LF; Viciana, Pompeyo; Girón González, José Antonio; Romero-Palacios, Alberto; Márquez Solero, Manuel; Martínez Pérez, María Ángeles; López Ruz, Miguel Ángel; De la Torre Lima, Javier; Delgado Fernández, Marcial; Gasrvía Lázaro, Milagros; Lozano, Fernando; Omar Mohamed-Balghata, MohamedEditorial
University of Rome Tor Vergata
Date
2014-05Referencia bibliográfica
López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, et al. (2014) Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE 9(5): e97262. doi:10.1371/journal.pone.0097262
Résumé
Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen
for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase
inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects
without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to
adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The
primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to
suppress plasma HIV-RNA to ,50 copies/mL after 24 weeks on treatment, or a confirmed viral load .200 copies/mL in
patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty
seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9–92.1%) and 77.4% (CI95,
65.0–89.7%), respectively; the rates reached 97.2% (CI95, 95.1–99.3%) and 90.5% (CI95, 81.7–99.3), by on-treatment analysis.
The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1–2 adverse events were observed
motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable,
well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug
activity.